Beijing Meibo Pharmaceutical Biotechnology Development Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2019

Location

Beijing China

Primary Industry

Healthcare

About

Established in 2019 and based in Beijing, China, Beijing Meibo Pharmaceutical Biotechnology Development operates as a pharmaceutical biotechnology company that focuses on human-source ECM regenerated new materials R&D. Dr. E Xiao, the company's co-founder and chairman, former founder of the Molecular Biology Platform of Oral and Maxillofacial Surgery of Peking University. In 2022, it won the "VB-Find Award for the Top 100 Most Innovative Medical Technology Products (Solutions)". In September 2023, the company closed series A+ funding from Beijing New Aerotropolis Fund management, Hunan Chasing Fund Management and Sunz Fund. It cooperates with Central South University, Hunan University, Sichuan University and Nanjing University, etc. The company provides regenerative bioscaffold materials for maxillofacial defects and deformity repair in the field of medical aesthetics. It uses human extracellular matrix (ECM) technology to establish a sterile processing production line for prefilled needles. Products include Meiweiti-Ya, Yao and Nuo series products.

Current Investors

Redhill Capital, Alwin Capital, Century Golden Resources Group

Request a demo to show more

Primary Industry

Healthcare

Sub Industries

Beauty & Hygiene, Biopharmaceuticals, Aesthetic Medicine, Biomaterials

Verticals

Manufacturing

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.